IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

10.43

-0.15 (-1.42%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	10.58
Open	10.52
Bid	10.15 x 2900
Ask	10.63 x 900
Day's Range	10.17 - 10.54
52 Week Range	4.26 - 13.41
Volume	1,334,375
Avg. Volume	2,712,357

Market Cap	1.388B
Beta	2.97
PE Ratio (TTM)	N/A
EPS (TTM)	-0.98
Earnings Date	Apr 27, 2017 - May 1, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	13.00

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire10 days ago
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha -positive ovarian cancer.
Thomson Reuters StreetEvents18 days ago
Edited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMT
Q1 2018 ImmunoGen Inc Earnings Call
Motley Fool18 days ago
ImmunoGen Presses Forward
The biotech waits for clinical trial results for its lead drug, mirvetuximab.
Zacks20 days ago
ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.
Zacks23 days ago
ImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat
ImmunoGen posted wider-than-expected loss in the first quarter of 2018. However, revenues surpassed estimates but decreased year over year.
Associated Press23 days ago
ImmunoGen: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Business Wire23 days ago
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
ACCESSWIRE23 days ago
ImmunoGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:00 AM Eastern Time. To listen ...
Business Wire24 days ago
ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease.
Zacks27 days ago
What's in Store for ImmunoGen (IMGN) This Earnings Season?
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.
Motley Fool29 days ago
Why ImmunoGen, Inc. Stock Is on the Rise Today
ImmunoGen's lead product candidate appears to be on the right track.
Market Exclusivelast month
Here’s Why The Immunogen News Is Important For The Company
ImmunoGen, Inc. (NASDAQ:IMGN) is attracting a substantial amount of attention in the biotechnology space as we head into the close of this week, with the company putting out a release outlining some progress for its lead investigative trial. On the back of the news, Immunogen shares are seeing plenty of movement, with the implications of […] The post Here’s Why The Immunogen News Is Important For The Company appeared first on Market Exclusive.
Business Wirelast month
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) based upon successful completion of a pre-specified interim futility analysis after 80 progression-free survival (PFS) events as determined by blinded, independent central review. ImmunoGen has also completed full enrollment of the trial two months ahead of schedule and expects top-line results from FORWARD I during the first half of 2019. “Ovarian cancer is the leading cause of death from gynecological cancers, and patients diagnosed with this life-threatening disease have limited treatment options, especially once they develop platinum-resistant disease,” said Anna Berkenblit, M.D., vice president and chief medical officer of ImmunoGen.
Business Wirelast month
ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
“As ImmunoGen continues to evolve, we look to complement our existing team with outside talent with experience to accelerate our transition to a fully-integrated biotechnology company delivering innovative products to improve outcomes for cancer patients,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
Business Wirelast month
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
Zackslast month
Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
Investors in ImmunoGen (IMGN) need to pay close attention to the stock based on moves in the options market lately.
Zacks2 months ago
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Benzinga2 months ago
The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences
Biotech stocks continued to be in the red this week, with the losses worse than what the broader market suffered. Here's a list of key events associated with biotech stocks one needs to focus on, in the ...
Motley Fool2 months ago
What Knocked ImmunoGen, Inc. Down 15% on Tuesday?
Investors were generally pleased with a data drop over the weekend, but it wasn't enough to keep ImmunoGen from tanking for no apparent reason on Tuesday.
Zacks2 months ago
ImmunoGen (IMGN) Jumps: Stock Rises 7%
ImmunoGen (IMGN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Business Wire2 months ago
ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer .
Zacks2 months ago
Is the Options Market Predicting a Spike in ImmunoGen (IMGN) Stock?
Investors in ImmunoGen (IMGN) need to pay close attention to the stock based on moves in the options market lately.
Benzinga2 months ago
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
Business Wire2 months ago
ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research Annual Meeting to be held from April 14-18, 2018 in Chicago.
MarketWatch2 months ago
Harry Boxer’s six stocks to watch, including two short-sale candidates
In focus: Immunogen, Kopin, Mindbody, Nutanix, Overstock.com and Dave & Buster’s.